Tandem Diabetes Care, Inc. is a US-based healthcare and biotechnology company that operates domestically. It specialises in supplying insulin pumps and glucose monitoring systems for children and adults who have insulin-dependent diabetic conditions. The company was founded in 2006 in San Diego, California, where its headquarters are located. It employs 1,500 people.
Tandem Diabetes’ key product is the t:slim X2 Insulin Delivery System, which is as much as 38% smaller than its competitors. It can be used as a standalone device or in conjunction with the Dexcom G6 continuous glucose monitoring (CGM) system and features a large touchscreen and remote software update functionality.
Other products in the Tandem Diabetes range include Basal-IQ technology and Control-IQ technology. Control IQ technology is designed to maximise the time a user stays within the target glycaemic range. Basal-IQ technology offers users a predictive suspend feature, whereby the delivery of insulin is suspended temporarily to minimise the risk of hypoglycaemic episodes.
Tandem Diabetes Inc. trades on the NASDAQ using the ticker TNDM. The company works with a network of distribution partners in 21 countries, including Australia, Canada, South Africa, and the United Kingdom.
Follow TNDM stock price changes and get the latest news on Tandem Diabetes with your eToro watchlist.